CD8A and adenocarcinoma: While treatment with Mito‐ATO caused a regression of the nontreated side established LKR13 adenocarcinoma in mice in which T cells had not been depleted, the antitumor effect of Mito‐ATO was abolished in mice in which CD4+ T cells were depleted; a much smaller decrease in Mito‐ATO's effect was observed in mice that were depleted of CD8+ T cells (Figure 2N).